[C:1]1([C:7](=[C:9]2[C:17]3[C:12](=[CH:13][CH:14]=[CH:15][CH:16]=3)[NH:11][C:10]2=[O:18])[CH3:8])[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.Br[CH2:20][C:21]([O:23][CH3:24])=[O:22].C([O-])([O-])=O.[Cs+].[Cs+]>CN(C=O)C>[CH3:24][O:23][C:21](=[O:22])[CH2:20][N:11]1[C:12]2[C:17](=[CH:16][CH:15]=[CH:14][CH:13]=2)[C:9](=[C:7]([C:1]2[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=2)[CH3:8])[C:10]1=[O:18]3-(1-Phenyl-ethylidene)-1,3-dihydro-indol-2-one (294 mg, 1 mmol) was dissolved in anhydrous DMF, then methyl bromoacetate (184 mg, 1.2 mmol) was added. Finally, Cs2CO3 (488 mg, 1.5 mmol) was added in one portion. The mixture was stirred at room temperature overnight. The reaction was monitored by HPLC. When the reaction was finished, the solvent was removed under reduced pressure. The residue was separated by flash chromatography column (gradient elution, 5-10% ethyl acetate in petroleum ether) to give [2-oxo-3-(1-phenyl-ethylidene)-2,3-dihydro-indol-1-yl]-acetic acid methyl ester as yellow powder (230 mg, 75%). MS calcd. for C19H17NO3 307, obsd. (ESI+) [(M+1)+] 308.1.